Laureate Pharma, Inc. (Princeton, NJ), has entered into contract manufacturing agreements with Tolerx, Inc. (Cambridge, MA), and Tolera Therapeutics, Inc. (Kalamazoo, MI).
Laureate Pharma, Inc. (Princeton, NJ), has entered into contract manufacturing agreements with Tolerx, Inc. (Cambridge, MA), and Tolera Therapeutics, Inc. (Kalamazoo, MI).
Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases. Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.
Laureate has also entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops and offers targeted therapies and solutions for immune modulation and related medical needs. According to the agreement, Laureate will produce Tolera’s TOL101 MAb under cGMP conditions to be used in clinical trials. Terms of the manufacturing agreement were not disclosed.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.